RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration

Summary

This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study medication. Study treatment will be administered by intravitreal injections.

Timeline

Start

2021-06-15

Primary completion

2022-02-08

Completion

2022-03-04

Drugs

Indications